Moderna
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +409.2% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 8.3% of float.
- Analyst tilt is Hold.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 54.8% | Better than 69% |
| Operating margin | -159.9% | Better than 6% |
| Net margin | -146.8% | Better than 6% |
| Return on equity | -28.9% | Better than 13% |
| Return on invested capital | -28.2% | Better than 11% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 34.4% | Better than 99% |
| 6-month return | 316.0% | Better than 100% |
| 12-month return (ex latest month) | 754.3% | Better than 100% |
| Distance below 52-week high | 30.6% | Better than 42% |
Financial Health C
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.3x | Better than 76% |
| Debt to assets | 10.6% | Better than 69% |
| Interest coverage | -275.8x | Better than 3% |
| Free cash flow / net income | 54.8% | Better than 15% |
Analyst View F
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 15.4% | Better than 7% |
| Upside to average target | -24.8% | Better than 0% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 199.33
- Open
- 200.07
- Day range
- 191.46 - 210.00
- Avg price
- 199.48
- Volume
- 9.69M
- Turnover
- 1.93B
- Turnover ratei
- 2.60%
- Volume ratioi
- 1.25
- Amplitudei
- 9.30%
- 52-week rangei
- 23.55 - 280.80
Valuation
- P/Ei
- -26.86
- P/E (TTM)i
- -27.70
- P/Bi
- 11.54
- EPSi
- -7.26
- Book value / shi
- 16.90
- Net profit
- -2.94B
- Net assets
- 6.84B
Share structure
- Market cap
- 78.90B
- Float capi
- 72.59B
- Shares out
- 404.62M
- Float sharesi
- 372.26M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-12-07
30.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+404.17M net over the window
Short interest
- Shares short
- 33.19M
- % of floati
- 8.31%
- Days to coveri
- 1.76
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Moderna (MRNA)?
Moderna last traded at 195.00. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Moderna's market cap?
About 78.90B.
What is the P/E ratio of Moderna?
The trailing twelve-month P/E is -27.70. The Valuation tab shows it against the stock's own five-year range.
Does Moderna pay a dividend?
Moderna does not currently pay a regular dividend.
Is Moderna a buy according to analysts?
The consensus of 13 analysts is a Hold rating, with an average 12-month price target of 146.67, which implies 24.8% downside from the current price. This is not investment advice.
What is Moderna's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Moderna a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.
Moderna discussion 0 comments